Therapeutics to prevent allergic reactions
Background
Food allergies, in particular, allergy to peanuts, are a serious public health concern that can culminate in death.There are more than 150 million people affected by allergic disease in Europe and 7 million of them suffer from food allergy. This 150 million figure is predicted to increase exponentially and it is estimated that by 2025 more than 50% of all Europeans will suffer from at least one type of allergy, with no age, social or geographical distinction.
Description of the Invention
Type I allergy is characterized by the production of immunoglobulin E (IgE) antibodies, against otherwise harmless antigens. Our novel peanut allergy therapy constitutes of IgE epitope-like peptides, that bind to specific IgEs and Ara h 2- specific IgEs on the surface of effector cells of patients with allergy to peanuts. Consequently, degranulation and segregation of mediators in the allergic reaction are prevented.
Main Advantages
Currently, there is no definitive treatment for peanut allergy. Researchers are studying ant-IgE mAb (Omalizumab) and oral immunotherapy (desensitization), but so far this approaches have not deliver a permanent cure.
Get in touch with us
ipr@uni-lj.siSolutions to your challenges
More information